Model-Based Angiogenic Inhibition of Tumor Growth Using Modern Robust Control Method

Abstract Cancer is one of the most destructive and lethal illnesses of the modern civilization. In the last decades, clinical cancer research shifted towards molecular targeted therapies which have limited side effects in comparison to conventional chemotherapy and radiation therapy. Anti-angiogenic therapy is one of the most promising cancer treatment methods. The dynamical model for tumor growth under angiogenic stimulator/inhibitor control was posed by Hahnfeldt et al. (1999), and it was investigated and partly modified many times. In this paper, a modified version of the originally published model is used in order to describe a continuous infusion therapy. To generalize individualized therapies a robust control method is proposed using ℋ ∞ methodology. Uncertainty weighting functions are determined based on the real pathophysiological case and simulations are performed on different tumor volumes to demonstrate the robustness of the proposed method.

[1]  Levente Kovács,et al.  Model-based angiogenic inhibition of tumor growth using modern robust control method , 2014, Comput. Methods Programs Biomed..

[2]  Levente Kovács,et al.  Robust servo control of a novel type 1 diabetic model , 2011 .

[3]  Fusheng Tang,et al.  Modeling a simplified regulatory system of blood glucose at molecular levels. , 2008, Journal of theoretical biology.

[4]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[5]  H. Verheul,et al.  Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? , 2009, Angiogenesis.

[6]  R. Kerbel A cancer therapy resistant to resistance , 1997, Nature.

[7]  P. Khargonekar,et al.  State-space solutions to standard H/sub 2/ and H/sub infinity / control problems , 1989 .

[8]  Stefan Preitl,et al.  Optimisation criteria in development of fuzzy controllers with dynamics , 2004, Eng. Appl. Artif. Intell..

[9]  Feng Chen,et al.  A review on various targeted anticancer therapies , 2012, Targeted Oncology.

[10]  Daniel G Haller,et al.  Bevacizumab beyond progression: does this make sense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J M Pluda,et al.  Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. , 1997, Seminars in oncology.

[12]  Lin Yuan,et al.  Celastrus Orbiculatus Extract inhibits tumor angiogenesis by targeting vascular endothelial growth factor signaling pathway and shows potent antitumor activity in hepatocarcinomas in Vitro and in Vivo , 2012, Chinese Journal of Integrative Medicine.